Text Size

Molecular imaging reveals unique degenerative changes in experimental glaucoma

Lmamura K., Onoe H., Shimazawa M., Nozaki S., Wada Y., Kato K., Nakajima H., Mizuma H., Onoe K., Taniguchi T., Sasaoka M., Hara H., Tanaka S., Araie M., Watanabe Y.


  • 2009
  • NeuroReport
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Department of Systems Life Engineering, Maebashi Institute of Technology, Maebashi-shi, Japan; Department of Physiology, Osaka City University Graduate, School of Medicine, Osaka, Japan; Laboratory of Visual Neurocomputing, Brain Science Institute, RIKEN, Saitama, Japan; Molecular Imaging Research Program, RIKEN, Kobe, Japan; Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Mitahora-higashi, Gifu, Japan; Glaucoma Group, Research and Development Center, Santen Pharmaceutical Co. Ltd., Ikoma, Japan; Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; Department of Systems Life Engineering, Maebashi Institute of Technology, 460-1 Kamisadori-machi, Maebashi-shi, Gunma 371-0816, Japan

Related Publications

24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022